Search research articles
Contact Us
Filters
Showing results (61-70 of 89) with videos related to
Page
of 9
Sort By:
Blood
|
August 6, 2011
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, et al.
Annals of Hematology
|
April 21, 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, et al.
Plos One
|
November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis
Giuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Oncotarget
|
November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
Sara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 89) with videos related to
Sort By:
Page
of 9
Blood
|
August 6, 2011
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
Giuseppe Visani, Lara Malerba, Pietro Maria Stefani, et al.
Annals of Hematology
|
April 21, 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice
Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, et al.
Plos One
|
November 24, 2011
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis
Giuseppe Visani, Maria Rosaria Sapienza, Alessandro Isidori, et al.
Hematological Oncology
|
May 18, 2017
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Francesca Palandri, Mario Tiribelli, Giulia Benevolo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 25, 2025
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Francesca Palandri, Massimo Breccia, Erika Morsia, et al.
Hematological Oncology
|
April 16, 2019
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Francesca Palandri, Giuseppe A Palumbo, Elisabetta Abruzzese, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Oncotarget
|
November 21, 2017
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
Sara Galimberti, Cristina Bucelli, Elena Arrigoni, et al.
Page
of 9